image
Healthcare - Medical - Devices - NASDAQ - US
$ 38.72
1.65 %
$ 552 M
Market Cap
-47.22
P/E
1. INTRINSIC VALUE

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications.[ Read More ]

The intrinsic value of one SRDX stock under the base case scenario is HIDDEN Compared to the current market price of 38.7 USD, Surmodics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SRDX

image
FINANCIALS
126 M REVENUE
-4.91%
-5.64 M OPERATING INCOME
-109.61%
-11.5 M NET INCOME
-651.43%
248 K OPERATING CASH FLOW
-97.64%
-2.94 M INVESTING CASH FLOW
56.95%
-2.95 M FINANCING CASH FLOW
-16.03%
33.2 M REVENUE
9.51%
-613 K OPERATING INCOME
88.58%
-3.45 M NET INCOME
54.34%
3.66 M OPERATING CASH FLOW
279.93%
9.46 M INVESTING CASH FLOW
240.70%
-1.56 M FINANCING CASH FLOW
-2366.67%
Balance Sheet Decomposition Surmodics, Inc.
image
Current Assets 81.3 M
Cash & Short-Term Investments 40.1 M
Receivables 23.2 M
Other Current Assets 18 M
Non-Current Assets 97.3 M
Long-Term Investments 0
PP&E 25 M
Other Non-Current Assets 72.3 M
Current Liabilities 20.5 M
Accounts Payable 0
Short-Term Debt 0
Other Current Liabilities 20.5 M
Non-Current Liabilities 39.1 M
Long-Term Debt 29.6 M
Other Non-Current Liabilities 9.57 M
EFFICIENCY
Earnings Waterfall Surmodics, Inc.
image
Revenue 126 M
Cost Of Revenue 33 M
Gross Profit 93.1 M
Operating Expenses 98.7 M
Operating Income -5.64 M
Other Expenses 5.9 M
Net Income -11.5 M
RATIOS
73.81% GROSS MARGIN
73.81%
-4.48% OPERATING MARGIN
-4.48%
-9.15% NET MARGIN
-9.15%
-9.71% ROE
-9.71%
-6.46% ROA
-6.46%
-5.85% ROIC
-5.85%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Surmodics, Inc.
image
Net Income -11.5 M
Depreciation & Amortization 8.69 M
Capital Expenditures -3.49 M
Stock-Based Compensation 8.22 M
Change in Working Capital -5.36 M
Others 995 K
Free Cash Flow -3.24 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Surmodics, Inc.
image
Wall Street analysts predict an average 1-year price target for SRDX of $42 , with forecasts ranging from a low of $36 to a high of $46 .
SRDX Lowest Price Target Wall Street Target
36 USD -7.02%
SRDX Average Price Target Wall Street Target
42 USD 8.47%
SRDX Highest Price Target Wall Street Target
46 USD 18.80%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Surmodics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Nov 28, 2022
Sell 152 K USD
BEDOYA JOSE H
Director
- 4366
34.888 USD
2 years ago
Nov 11, 2022
Sell 91.5 K USD
KALICH RONALD B SR
Director
- 2733
33.4838 USD
2 years ago
Nov 14, 2022
Sell 91.5 K USD
DANTZKER DAVID
Director
- 2773
32.9991 USD
2 years ago
Apr 01, 2022
Sell 175 K USD
Maharaj Gary R
President & CEO
- 3900
44.9742 USD
2 years ago
Apr 01, 2022
Sell 4.56 K USD
Maharaj Gary R
President & CEO
- 100
45.55 USD
2 years ago
Feb 28, 2022
Sell 196 K USD
KNIGHT SUSAN E
Director
- 4366
44.9683 USD
2 years ago
Jan 04, 2022
Sell 125 K USD
Stich Joseph J.
SVP, HR and GM, IVD
- 2500
50 USD
2 years ago
Nov 30, 2021
Sell 245 K USD
BEDOYA JOSE H
Director
- 5576
44.0011 USD
2 years ago
Nov 24, 2021
Sell 163 K USD
DANTZKER DAVID
Director
- 3475
47.01 USD
3 years ago
Nov 01, 2021
Sell 317 K USD
Maharaj Gary R
President & CEO
- 5800
54.6302 USD
3 years ago
Nov 01, 2021
Sell 11 K USD
Maharaj Gary R
President & CEO
- 200
55.245 USD
3 years ago
Oct 01, 2021
Sell 308 K USD
Maharaj Gary R
President & CEO
- 5500
55.9692 USD
3 years ago
Oct 01, 2021
Sell 28.3 K USD
Maharaj Gary R
President & CEO
- 500
56.533 USD
3 years ago
Sep 15, 2021
Sell 58.4 K USD
Maharaj Gary R
President & CEO
- 1030
56.6824 USD
3 years ago
Sep 15, 2021
Sell 285 K USD
Maharaj Gary R
President & CEO
- 4970
57.3393 USD
3 years ago
Aug 31, 2021
Sell 77.2 K USD
OLSON CHARLES W
Senior VP of Bus Dev, Med Dev
- 1292
59.75 USD
3 years ago
Aug 19, 2021
Sell 136 K USD
Stich Joseph J.
SVP, HR and GM, IVD
- 2500
54.4009 USD
3 years ago
Aug 11, 2021
Sell 136 K USD
Manders John D.
Corporate Controller
- 2555
53.3312 USD
3 years ago
Aug 11, 2021
Sell 2.87 K USD
Manders John D.
Corporate Controller
- 53
54.24 USD
3 years ago
May 20, 2021
Sell 135 K USD
Stich Joseph J.
SVP, HR and GM, IVD
- 2500
53.8022 USD
3 years ago
Apr 28, 2021
Sell 90.1 K USD
OLSON CHARLES W
Senior VP of Bus Dev, Med Dev
- 1508
59.75 USD
3 years ago
Apr 16, 2021
Sell 38.7 K USD
OLSON CHARLES W
Senior VP of Bus Dev, Med Dev
- 648
59.75 USD
3 years ago
Mar 31, 2021
Sell 270 K USD
OLSON CHARLES W
Senior VP of Bus Dev, Med Dev
- 4759
56.75 USD
3 years ago
Mar 01, 2021
Sell 156 K USD
Maharaj Gary R
President & CEO
- 3001
51.8623 USD
3 years ago
Mar 01, 2021
Sell 52.6 K USD
Maharaj Gary R
President & CEO
- 999
52.6731 USD
3 years ago
Feb 26, 2021
Sell 292 K USD
KNIGHT SUSAN E
Director
- 5576
52.3593 USD
3 years ago
Feb 23, 2021
Sell 75.9 K USD
BEDOYA JOSE H
Director
- 1497
50.68 USD
3 years ago
Feb 16, 2021
Sell 104 K USD
Stich Joseph J.
SVP, HR and GM, IVD
- 2016
51.4993 USD
3 years ago
Feb 16, 2021
Sell 25.4 K USD
Stich Joseph J.
SVP, HR and GM, IVD
- 484
52.5082 USD
3 years ago
Feb 01, 2021
Sell 127 K USD
Maharaj Gary R
President & CEO
- 2843
44.7672 USD
3 years ago
Feb 01, 2021
Sell 7.15 K USD
Maharaj Gary R
President & CEO
- 157
45.54 USD
3 years ago
Jan 05, 2021
Sell 112 K USD
Stich Joseph J.
SVP, HR and GM, IVD
- 2500
45 USD
3 years ago
Jan 04, 2021
Sell 87.9 K USD
Maharaj Gary R
President & CEO
- 2000
43.9628 USD
4 years ago
Sep 01, 2020
Sell 135 K USD
Maharaj Gary R
President & CEO
- 3000
45.0688 USD
4 years ago
Aug 19, 2020
Sell 117 K USD
Stich Joseph J.
SVP, HR and GM, IVD
- 2500
46.7123 USD
4 years ago
Aug 03, 2020
Sell 142 K USD
Maharaj Gary R
President & CEO
- 3000
47.4446 USD
4 years ago
Jul 01, 2020
Sell 86 K USD
Maharaj Gary R
President & CEO
- 2000
43.0183 USD
4 years ago
Jun 09, 2020
Sell 112 K USD
Stich Joseph J.
SVP, HR and GM, IVD
- 2500
45 USD
4 years ago
Feb 20, 2020
Sell 68.3 K USD
BEDOYA JOSE H
Director
- 1821
37.5147 USD
4 years ago
Jan 02, 2020
Sell 28.8 K USD
Maharaj Gary R
President & CEO
- 702
41.0841 USD
4 years ago
Dec 02, 2019
Sell 172 K USD
Maharaj Gary R
President & CEO
- 4270
40.3303 USD
4 years ago
Dec 02, 2019
Sell 29.7 K USD
Maharaj Gary R
President & CEO
- 730
40.7437 USD
5 years ago
Nov 01, 2019
Sell 182 K USD
Maharaj Gary R
President & CEO
- 4500
40.5152 USD
5 years ago
Nov 01, 2019
Sell 20.6 K USD
Maharaj Gary R
President & CEO
- 500
41.288 USD
5 years ago
Oct 01, 2019
Sell 214 K USD
Maharaj Gary R
President & CEO
- 4700
45.4585 USD
5 years ago
Oct 01, 2019
Sell 13.8 K USD
Maharaj Gary R
President & CEO
- 300
46.1417 USD
5 years ago
Sep 23, 2019
Sell 92.6 K USD
Stich Joseph J.
VP and GM, IVD
- 2000
46.3156 USD
5 years ago
Sep 03, 2019
Sell 230 K USD
Maharaj Gary R
President & CEO
- 5000
45.9529 USD
5 years ago
Aug 01, 2019
Sell 94 K USD
Stich Joseph J.
VP and GM, IVD
- 2000
47 USD
5 years ago
Aug 01, 2019
Sell 103 K USD
Maharaj Gary R
President & CEO
- 2230
46.1495 USD
5 years ago
Aug 01, 2019
Sell 130 K USD
Maharaj Gary R
President & CEO
- 2770
46.7816 USD
5 years ago
Jul 01, 2019
Sell 83.1 K USD
Maharaj Gary R
President & CEO
- 1970
42.176 USD
5 years ago
Jul 01, 2019
Sell 130 K USD
Maharaj Gary R
President & CEO
- 3030
42.9738 USD
5 years ago
Jun 03, 2019
Sell 205 K USD
Maharaj Gary R
President & CEO
- 5000
40.9479 USD
5 years ago
May 01, 2019
Sell 213 K USD
Maharaj Gary R
President & CEO
- 5000
42.678 USD
5 years ago
Apr 01, 2019
Sell 214 K USD
Maharaj Gary R
President & CEO
- 5000
42.8996 USD
5 years ago
Mar 29, 2019
Sell 85.5 K USD
Stich Joseph J.
VP and GM, IVD
- 1900
45 USD
5 years ago
Mar 22, 2019
Sell 4.55 K USD
Stich Joseph J.
VP and GM, IVD
- 100
45.54 USD
5 years ago
Feb 25, 2019
Sell 147 K USD
Heine Lisa Wipperman
Director
- 2569
57.3795 USD
5 years ago
Feb 15, 2019
Sell 32.7 K USD
Stich Joseph J.
VP and GM, IVD
- 600
54.4367 USD
5 years ago
Feb 15, 2019
Sell 61.1 K USD
Stich Joseph J.
VP and GM, IVD
- 1103
55.4169 USD
5 years ago
Feb 15, 2019
Sell 16.7 K USD
Stich Joseph J.
VP and GM, IVD
- 297
56.297 USD
6 years ago
Oct 01, 2018
Sell 295 K USD
Maharaj Gary R
President & CEO
- 4100
72.0366 USD
6 years ago
Oct 01, 2018
Sell 14.6 K USD
Maharaj Gary R
President & CEO
- 200
72.75 USD
6 years ago
Oct 01, 2018
Sell 51.9 K USD
Maharaj Gary R
President & CEO
- 700
74.1043 USD
5 years ago
Feb 01, 2019
Sell 34.6 K USD
Maharaj Gary R
President & CEO
- 668
51.8681 USD
5 years ago
Feb 01, 2019
Sell 49.1 K USD
Maharaj Gary R
President & CEO
- 925
53.0502 USD
5 years ago
Feb 01, 2019
Sell 45.4 K USD
Maharaj Gary R
President & CEO
- 840
54.049 USD
5 years ago
Feb 01, 2019
Sell 16.7 K USD
Maharaj Gary R
President & CEO
- 300
55.53 USD
5 years ago
Feb 01, 2019
Sell 5.64 K USD
Maharaj Gary R
President & CEO
- 100
56.36 USD
5 years ago
Jan 02, 2019
Sell 226 K USD
Maharaj Gary R
President & CEO
- 4900
46.2045 USD
5 years ago
Jan 02, 2019
Sell 4.68 K USD
Maharaj Gary R
President & CEO
- 100
46.83 USD
5 years ago
Dec 03, 2018
Sell 150 K USD
Maharaj Gary R
President & CEO
- 2547
58.8504 USD
5 years ago
Dec 03, 2018
Sell 92.8 K USD
Maharaj Gary R
President & CEO
- 1557
59.5725 USD
5 years ago
Dec 03, 2018
Sell 54.1 K USD
Maharaj Gary R
President & CEO
- 896
60.3786 USD
6 years ago
Nov 09, 2018
Sell 12.4 K USD
Stich Joseph J.
VP and GM, IVD
- 200
62.07 USD
6 years ago
Nov 09, 2018
Sell 66.5 K USD
Stich Joseph J.
VP and GM, IVD
- 1046
63.6076 USD
6 years ago
Nov 09, 2018
Sell 48.6 K USD
Stich Joseph J.
VP and GM, IVD
- 754
64.4499 USD
6 years ago
Nov 01, 2018
Sell 260 K USD
Maharaj Gary R
President & CEO
- 4193
62.1251 USD
6 years ago
Nov 01, 2018
Sell 50.6 K USD
Maharaj Gary R
President & CEO
- 807
62.6427 USD
6 years ago
Sep 04, 2018
Sell 294 K USD
Maharaj Gary R
President & CEO
- 3700
79.4007 USD
6 years ago
Sep 04, 2018
Sell 104 K USD
Maharaj Gary R
President & CEO
- 1300
80.1639 USD
6 years ago
Aug 23, 2018
Sell 1.05 M USD
Sutton Gregg S
VP of Research and Development
- 14204
74.1079 USD
6 years ago
Aug 23, 2018
Sell 46.5 K USD
Sutton Gregg S
VP of Research and Development
- 620
74.9419 USD
6 years ago
Aug 16, 2018
Sell 438 K USD
KNIGHT SUSAN E
Director
- 6000
72.93 USD
6 years ago
Aug 10, 2018
Sell 6.73 K USD
Stich Joseph J.
VP and GM, IVD
- 100
67.3 USD
6 years ago
Aug 10, 2018
Sell 13.7 K USD
Stich Joseph J.
VP and GM, IVD
- 200
68.425 USD
6 years ago
Aug 10, 2018
Sell 119 K USD
Stich Joseph J.
VP and GM, IVD
- 1700
70.0596 USD
6 years ago
Aug 01, 2018
Sell 295 K USD
Maharaj Gary R
President & CEO
- 5000
58.9254 USD
6 years ago
Jul 02, 2018
Sell 272 K USD
Maharaj Gary R
President & CEO
- 5000
54.48 USD
6 years ago
Jun 11, 2018
Sell 550 K USD
OLSON CHARLES W
Senior VP of Bus Dev, Med Dev
- 10000
55.002 USD
6 years ago
Jun 06, 2018
Sell 712 K USD
Phillips Bryan K
SVP, Gen Counsel & Secretary
- 13788
51.6235 USD
6 years ago
Jun 06, 2018
Sell 64 K USD
Phillips Bryan K
SVP, Gen Counsel & Secretary
- 1212
52.8122 USD
6 years ago
Jun 05, 2018
Sell 46.3 K USD
Stich Joseph J.
VP and GM, IVD
- 890
52.0039 USD
6 years ago
Jun 05, 2018
Sell 58.6 K USD
Stich Joseph J.
VP and GM, IVD
- 1110
52.7941 USD
7. News
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why SurModics (SRDX) could produce exceptional returns because of its solid growth attributes. zacks.com - 4 days ago
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate. zacks.com - 1 week ago
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago. zacks.com - 1 week ago
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C. PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce™. businesswire.com - 2 weeks ago
SRDX Stock Down Despite FDA Clearance for Pounce XL System Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market. zacks.com - 1 month ago
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 2 months ago
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 2 months ago
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 3 months ago
Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 3 months ago
SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago. zacks.com - 3 months ago
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. – SRDX NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc . ( Nasdaq : SRDX ), relating to its proposed sale to GTCR LLC. Under the terms of the agreement, Surmodics, Inc. shareholders will receive $43.00 in cash per share of Surmodics stock they own. globenewswire.com - 4 months ago
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX ), relating to its proposed sale to GTCR LLC. prnewswire.com - 4 months ago
8. Profile Summary

Surmodics, Inc. SRDX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 552 M
Dividend Yield 0.00%
Description Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Contact 9924 West 74th Street, Eden Prairie, MN, 55344-3523 https://www.surmodics.com
IPO Date March 4, 1998
Employees 376
Officers Ms. Teryl L. W. Sides Senior Vice President & President of Vascular Interventions Mr. Joseph J. Stich Senior Vice President of Human Resources & President of In Vitro Diagnostics Mr. John D. Manders Corporate Controller, Vice President of Finance & Principal Accounting Officer Mr. Charles W. Olson Senior Vice President & President of Medical Device Coatings Joel Suiter Director of Corporate Development Mr. Gordon S. Weber J.D. Senior Vice President of Legal, General Counsel & Secretary Mr. Gary R. Maharaj Chief Executive Officer, President & Director Mr. Timothy J. Arens Senior Vice President of Finance & Information Technology and Chief Financial Officer